Identification of SET7/9-E2F1 as Novel Therapeutic Biomarkers in Hepatocellular Carcinoma
Identification of SET7/9-E2F1 as Novel Therapeutic Biomarkers in Hepatocellular Carcinoma
Lu Xie1,2,3,4,5, Ye Gu1,2,3,4, Qiang Liu1,2,3,4, Hongzhang Shen1,2,3,4, Yifeng Zhou1,2,3,4, Jiangfeng Yang1,2,3,4, Xiaofeng Zhang1,2,3,4* and Jinyu Huang1,5*
ABSTRACT
Our previous studies have shown that SET7/9 promotes hepatocellular carcinoma cells proliferation, invasion and migration via post‑translational regulation of E2F1. In this study, we comprehensively analyzed the functions and mechanisms of the SET7/9-E2F1 axis using data mining. Data from the UALCAN database showed abnormal expression of both SET7/9 and E2F1 in multiple cancer types. Survival curves and correlation analysis by GEPIA supported the significant roles of SET7/9 and E2F1 in the progression of HCC. Functional enrichment analysis suggested that the SET7/9-E2F1 axis is involved in the regulation of cell cycle, DNA repair and replication, and gene transcription. Our results implicated the potential of SET7/9 in combination with E2F1 as novel therapeutic targets and prognostic biomarkers in hepatocellular carcinoma.
To share on other social networks, click on any share button. What are these?
